- Home
- MDCX vs LSTA Comparison
MDCX vs LSTA Comparison
Compare MDCX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- LSTA
- Stock Information
- Founded
- MDCX 2008
- LSTA 1980
- Country
- MDCX Canada
- LSTA United States
- Employees
- MDCX N/A
- LSTA 26
- Industry
- MDCX
- LSTA Misc Health and Biotechnology Services
- Sector
- MDCX
- LSTA Health Care
- Exchange
- MDCX Nasdaq
- LSTA Nasdaq
- Market Cap
- MDCX 44.0M
- LSTA 22.5M
- IPO Year
- MDCX N/A
- LSTA N/A
- Fundamental
- Price
- MDCX $3.10
- LSTA $2.72
- Analyst Decision
- MDCX Strong Buy
- LSTA Strong Buy
- Analyst Count
- MDCX 2
- LSTA 1
- Target Price
- MDCX $23.50
- LSTA $15.00
- AVG Volume (30 Days)
- MDCX 480.6K
- LSTA 23.4K
- Earning Date
- MDCX 08-22-2025
- LSTA 08-11-2025
- Dividend Yield
- MDCX N/A
- LSTA N/A
- EPS Growth
- MDCX N/A
- LSTA N/A
- EPS
- MDCX N/A
- LSTA N/A
- Revenue
- MDCX N/A
- LSTA $1,000,000.00
- Revenue This Year
- MDCX N/A
- LSTA N/A
- Revenue Next Year
- MDCX N/A
- LSTA N/A
- P/E Ratio
- MDCX N/A
- LSTA N/A
- Revenue Growth
- MDCX N/A
- LSTA N/A
- 52 Week Low
- MDCX $1.80
- LSTA $1.87
- 52 Week High
- MDCX $8.94
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- LSTA 52.43
- Support Level
- MDCX N/A
- LSTA $2.34
- Resistance Level
- MDCX N/A
- LSTA $3.09
- Average True Range (ATR)
- MDCX 0.00
- LSTA 0.25
- MACD
- MDCX 0.00
- LSTA 0.01
- Stochastic Oscillator
- MDCX 0.00
- LSTA 50.67
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.